Destiny Pharma announces research collaboration with Aston University to investigate new XF-platform drug candidates

Research to investigate potential antimicrobial candidates against biofilms Brighton, United Kingdom – 17 July 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), today announces it has signed a three-year research collaboration agreement with Aston University. The […]

Destiny Pharma notes FDA statement on their focus to enable new approaches to fight AMR

Brighton, United Kingdom – 14 June 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), notes the FDA Commissioner, Scott Gottlieb M.D.’s further announcements this week outlining the regulator’s support of new incentives for companies developing novel […]

Scientific Advisory Board

Destiny Pharma has a Scientific Advisory Board (SAB) of key opinion leaders in relevant fields to help guide and inform the future clinical development of the XF platform.  Our SAB includes the following members: David Roblin MD FRCP FFPM FMedSci (SAB Chairman) Professor David Roblin is President of Research and Development at Summit Therapeutics. David […]

Destiny Pharma Clinical update

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the company”) Destiny Pharma […]

Destiny Pharma announces FDA Fast Track Designation for lead clinical candidate, exeporfinium chloride (XF-73)

Posted on 15/03/2018 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.  Destiny Pharma plc (“Destiny Pharma” or “the Company”) […]

Destiny Pharma wins Deal of the Year at the Insider South East Dealmaker Awards 2018

Posted on 05/02/2018 Destiny Pharma has won Deal of the Year at the Insider South East Dealmakers Awards 2018, held on 1 February 2018 at The Copthorne in Gatwick, UK. Now in its twelfth year, the Dealmakers awards recognise the region’s top deals and advisory companies over the course of the last 12 months.  The Deal […]

China Medical System Holdings Limited invests £3.0 million in Destiny Pharma

Posted on 01/12/2017 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) […]

Scottish Medicines Consortium Accepts Bronchitol For Use In Cystic Fibrosis Patients

Link here. Pharmaceutical company Pharmaxis (ASX:PXS) today announced that the Scottish Medicines Consortium (SMC) has accepted Bronchitol® (mannitol dry powder for inhalation) for use by the National Health Service in Scotland.  Bronchitol is licensed for the treatment of adult cystic fibrosis (CF) patients aged 18 years and above as an add-on therapy to best standard of […]

19.09.2013 – Pharmaxis Announces Two Board Retirements

Pharmaxis announcement link here. Pharmaceutical company Pharmaxis today announced the retirement of two non‐executive directors, Dr John Villiger and Mr Richard van den Broek. Dr Villiger joined the Board in November 2006. His career in the global pharmaceutical industry as a founder of The Medicines Company Inc. brought considerable clinical, regulatory and entrepreneurial experience to the […]